行情

CNAT

CNAT

Conatus制药
NASDAQ

实时行情|Nasdaq Last Sale

0.3385
-0.0054
-1.57%
盘前: 0.3301 -0.0084 -2.48% 08:47 10/23 EDT
开盘
0.3451
昨收
0.3439
最高
0.3600
最低
0.3250
成交量
2.78万
成交额
--
52周最高
5.89
52周最低
0.2500
市值
1,122.82万
市盈率(TTM)
-0.7686
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CNAT 新闻

  • 美国经济仍未摆脱险境 机构认为美元已经见顶
  • 汇通网.1小时前
  • 印尼狮航空难最终报告将公布 波音客机设计存缺陷
  • 央视.2小时前
  • 黑石集团第三季度净流入204亿美元,同比减少15%。管理资产5,540亿美...
  • 新浪财经.2小时前
  • 美药企称研发世界首款“有效”阿兹海默药 仍待获批
  • 澎湃新闻.2小时前

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

CNAT 简况

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
展开

Webull提供Conatus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。